Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Currency in USD	2026
Operating Income	140.85 Million
Income Before Tax	132.10 Million
Income Tax Expense	28.70 Million
Net Income	103.40 Million
Eps	0.50
Epsdiluted	0.50
Weighted Average Shs Out	206.35 Million
Weighted Average Shs Out Dil	207.83 Million
Depreciation And Amortization	50.55 Million
Interest Expense	10.02 Million
Ebit	142.13 Million
Interest Income	9.36 Million
Net Interest Income	-661 Thousand
Period	Q2
Ebitda	191.41 Million
Net Cash Provided By Operating Activities	N/A
Source	yahoo

Qiagen N.V. Annual Reports (10-K)